Background The optimal surgical management of larger chronic osteochondral lesions of the talus (OLT) remains debated. This study describes 24-month clinical and MRI outcomes after a combined single-stage matrix-assisted procedure using debridement, bone-marrow stimulation, autologous bone marrow-derived cell concentrate, a type I collagen scaffold, and fibrin glue.Methods This exploratory retrospective case series screened consecutive patients treated between January 2016 and December 2020. Twenty-six patients were identified; 15 had sufficiently complete clinical and MRI data for the predefined 24-month complete-case analysis. Eligible lesions were classified as Giannini type II-IIA and Outerbridge grade III-IV. The principal clinical endpoint was the 24-month change in the American Orthopaedic Foot Ankle Society (AOFAS) Ankle-Hindfoot score. Secondary outcomes included Visual Analogue Scale (VAS) pain, 24-month MRI morphology assessed with the MOCART system, and reoperations. Six- and 12-month assessments were part of routine care but were not sufficiently complete for formal longitudinal analysis.Results The mean AOFAS score increased from 57.3 +/- 12.0 at baseline to 92.4 +/- 7.1 at 24 months, an absolute improvement of 35.1 points. The mean VAS score decreased from 4.7 +/- 1.2 to 1.8 +/- 0.8, an absolute reduction of 2.9 points. At 24 months, complete defect filling was observed in 12 of 15 patients (80.0%), hypertrophic filling in 2 (13.3%), and incomplete filling in 1 (6.7%). Complete integration with adjacent tissue was observed in 14 patients (93.3%); preserved surface morphology and uniform repair-tissue structure were each observed in 12 (80.0%). Mean MOCART score was 83.7 +/- 14.4. Three patients (20.0%) underwent arthroscopic reoperation for symptomatic anterior impingement.Conclusion In this retrospective cohort, the combined single-stage procedure was associated with improved 24-month pain and functional scores and favorable MRI morphology of repair tissue. The uncontrolled design and multimodal procedure do not establish comparative efficacy, superiority, or an independent cell-specific treatment effect. Larger prospective controlled studies are needed.

Single-stage matrix-assisted bone marrow-derived cell concentrate implantation for osteochondral talar lesions: a 24-month clinical and MRI follow-up / Caggiari, G., Rinaldi, M., Santandrea, A., Mercurio, D., Lugani, G., D'Alessandro, S., Deng, H., Migliorini, F., Pisanu, F., Doria, C., Cortese, F., Puddu, L.. - In: FRONTIERS IN SURGERY. - ISSN 2296-875X. - 13:(2026). [10.3389/fsurg.2026.1941433]

Single-stage matrix-assisted bone marrow-derived cell concentrate implantation for osteochondral talar lesions: a 24-month clinical and MRI follow-up

Caggiari, Gianfilippo;Rinaldi, Michelangelo;Santandrea, Alessandro;D'Alessandro, Silvia;Pisanu, Francesco;Doria, Carlo;Puddu, Leonardo
2026-01-01

Abstract

Background The optimal surgical management of larger chronic osteochondral lesions of the talus (OLT) remains debated. This study describes 24-month clinical and MRI outcomes after a combined single-stage matrix-assisted procedure using debridement, bone-marrow stimulation, autologous bone marrow-derived cell concentrate, a type I collagen scaffold, and fibrin glue.Methods This exploratory retrospective case series screened consecutive patients treated between January 2016 and December 2020. Twenty-six patients were identified; 15 had sufficiently complete clinical and MRI data for the predefined 24-month complete-case analysis. Eligible lesions were classified as Giannini type II-IIA and Outerbridge grade III-IV. The principal clinical endpoint was the 24-month change in the American Orthopaedic Foot Ankle Society (AOFAS) Ankle-Hindfoot score. Secondary outcomes included Visual Analogue Scale (VAS) pain, 24-month MRI morphology assessed with the MOCART system, and reoperations. Six- and 12-month assessments were part of routine care but were not sufficiently complete for formal longitudinal analysis.Results The mean AOFAS score increased from 57.3 +/- 12.0 at baseline to 92.4 +/- 7.1 at 24 months, an absolute improvement of 35.1 points. The mean VAS score decreased from 4.7 +/- 1.2 to 1.8 +/- 0.8, an absolute reduction of 2.9 points. At 24 months, complete defect filling was observed in 12 of 15 patients (80.0%), hypertrophic filling in 2 (13.3%), and incomplete filling in 1 (6.7%). Complete integration with adjacent tissue was observed in 14 patients (93.3%); preserved surface morphology and uniform repair-tissue structure were each observed in 12 (80.0%). Mean MOCART score was 83.7 +/- 14.4. Three patients (20.0%) underwent arthroscopic reoperation for symptomatic anterior impingement.Conclusion In this retrospective cohort, the combined single-stage procedure was associated with improved 24-month pain and functional scores and favorable MRI morphology of repair tissue. The uncontrolled design and multimodal procedure do not establish comparative efficacy, superiority, or an independent cell-specific treatment effect. Larger prospective controlled studies are needed.
2026
Single-stage matrix-assisted bone marrow-derived cell concentrate implantation for osteochondral talar lesions: a 24-month clinical and MRI follow-up / Caggiari, G., Rinaldi, M., Santandrea, A., Mercurio, D., Lugani, G., D'Alessandro, S., Deng, H., Migliorini, F., Pisanu, F., Doria, C., Cortese, F., Puddu, L.. - In: FRONTIERS IN SURGERY. - ISSN 2296-875X. - 13:(2026). [10.3389/fsurg.2026.1941433]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/394429
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact